The Curtain Rises On DNAProtein Interactions
For the first time, scientists have watched proteins interact with long single-stranded DNA molecules in real time.The new method should yield insights into DNA replication and repair, the researchers say.
For the first time, scientists have watched proteins interact with long single-stranded DNA molecules in real time (Anal. Chem., DOI: 10.1021/ac302117z). The new method should yield insights into DNA replication and repair, the researchers say.
Until now, scientists could only watch proteins interacting with double-stranded DNA or very short single strands, says Eric Greene of Columbia University, who developed the new method. But, he says, “Basically anything to do with DNA metabolism or DNA repair involves single-stranded DNA intermediates.”
To find a way to monitor long single strands, Greene built upon a method his team devised six years ago, which visualizes proteins binding to double-stranded DNA (Langmuir, DOI: 10.1021/la051944a). They tethered fluorescent DNA molecules to lipids in a bilayer that coated the surface of a microfluidic sample chamber. When the researchers flowed buffer through the chamber, the DNA molecules diffused within the bilayer, eventually aligning along a nanofabricated barrier in the bilayer. The researchers added proteins to the chamber and observed their interactions with DNA in real time by noting changes in the DNA’s fluorescent signal. The team called the method “DNA curtains” because the hundreds of aligned DNA strands—visualized by total internal reflection fluorescence microscopy—reminded them of a window curtain.
But the technique didn’t work with single-stranded DNA, which is so flexible that it often folds upon itself into extensive secondary structures that preclude protein binding. Also, the intercalating fluorescent dyes that label double-stranded DNA can break single strands of DNA.
So Greene and his coworkers found a way to simultaneously unravel folded-up single-stranded DNA and fluorescently label it. The key was a protein called replication protein A (RPA), which binds single strands during DNA replication to prevent them from folding up. When the researchers added a fluorescently labeled version of the protein to a DNA-curtains assay, it coated single-stranded DNA molecules, helping extend the DNA and keep it accessible to proteins. Because RPA coats all single-stranded DNA in cells, the researchers say, the ubiquitous protein is unlikely to interfere with the binding of other proteins.
To test whether the assay could visualize interactions of single-stranded DNA with other proteins, the team injected fluorescently tagged Sgs1 protein into a flow cell containing RPA-bound DNA curtains. Sgs1 is a yeast helicase protein involved in DNA repair. Using fluorescence microscopy to visualize the labeled RPA and Sgs1 proteins, the researchers watched Sgs1 bind single-stranded DNA in real time.
Greene says that the new assay will allow researchers to probe when and where proteins bind single-stranded DNA, and how multiple proteins influence each other’s binding. “We can watch all of this stuff as it happens,” he says.
Maria Spies of the University of Iowa says, “The DNA curtains approach combines the benefits of single-molecule and bulk studies.” That’s because, she explains, researchers can use it to visualize hundreds of single-stranded DNA molecules at the same time. “I can’t wait to try this system in my lab,” she says.
Related News
-
News Understanding the Benefits and Advances of Cleanroom Technology
In an industry where precision and sterility are crucial concerns, cleanrooms play a vital role in maintaining the integrity of pharmaceutical products like drugs, vaccines, and other medical products. So, what is a cleanroom?
-
News AbbVie secures GBP£1.2 billion deal for Gilgamesh’s psychedelic programme
AbbVie has penned a significant agreement to acquire the bretisilocin programme from Gilgamesh Pharmaceuticals for up to £1.2 billion, marking a bold step in the pharmaceutical giant's quest to develop treatments for psychiatric disorders. -
News Gates Foundation commits US$2.5 billion to women’s health research
The Bill & Melinda Gates Foundation has announced a substantial US$2.5 billion commitment to accelerate research and development focused exclusively on women's health through 2030.
-
News Mid-year review: notable FDA drug approvals of 2025
As we fly past the halfway point of 2025, the pharmaceutical landscape reliably continues to evolve with innovative therapies addressing critical medical needs. The FDA has already approved 17 groundbreaking medications this year, each representin... -
News US FDA announces new priority vouchers for accelerated review times
The US FDA announced a new priority program for drug developers – the Commissioner’s National Priority Voucher (CNPV) program aims to enhance the health interests of the US by allowing drug developers to redeem a voucher, shortening th... -
News Google-backed start-up raises US$600 million to support AI drug discovery and design
London-based Isomorphic Labs, an AI-driven drug design and development start-up backed by Google’s AI research lab DeepMind, has raised US$600 million in its first external funding round by Thrive Capital. The funding will provide further power t... -
News AstraZeneca to invest US$2.5 billion in Beijing R&D centre
Amid investigations of former AstraZeneca China head Leon Wang in 2024, AstraZeneca have outlined plans to establish its sixth global strategic R&D centre in China. Their aim is to further advance life sciences in China with major research and manufact... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience.